A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd in combination with Vitamin D on the progression to type 1 diabetes in children with multiple islet cell autoantibodies

Trial Profile

A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd in combination with Vitamin D on the progression to type 1 diabetes in children with multiple islet cell autoantibodies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Vitamin D
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DiAPREV-IT 2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 According to a Diamyd Medical media release, 26 patients have been included thus far in this trial.
    • 09 Mar 2016 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top